Diabetes In India

Diabetes cannot prevent you from getting a policy. You must disclose it as a pre-existing illness, but insurers cannot deny cover solely on this basis

Every year on November 14, we observe the World Diabetes Day (WDD) to increase awareness of diabetes, a chronic condition that affects millions of people worldwide

Indian diets, traditionally rich in whole grains, fruits, and vegetables, have shifted towards processed, fried, and sugar-laden foods, according to a recent government-backed study

Staying up late increases Type 2 diabetes risk by nearly 50 per cent and is associated with higher BMI, larger waist circumference, and more visceral and liver fat

Indians need simple, easy-to-understand, and prominent warning labels, so that their better natures are given a chance to overtake their impulses

A 59-year-old man with type 2 diabetes received an innovative cell transplant and has been insulin-free and off medication for 33 months, offering hope to other diabetes patients

The sales of Novo Nordisk's Rybelsus tablet, used for diabetes treatment and weight reduction, more than doubled to Rs 363 crore this year from Rs 147 crore last year

Findings based on research conducted by microbiome-based company Leucine Rich Bio using its flagship technology BugSpeaks

Covid-19 was the leading cause of death in India, as per the study. The age-standardised rate of deaths for both males and females was 156.8 per 100,000 population

Diabetes is an epidemic in India, with nearly 100 million Indians suffering from it. Diabetes has also been identified as the leading cause of chronic kidney disease in India

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

India is often dubbed as the diabetic capital of the world where nearly 11 per cent of the population is grappling with the disease

The company said that Zituvimet has undergone quality testing for Nitrosamines and potential genotoxic impurities according to current FDA standards

About 20 per cent or one in five adults considered healthy by medical standards, have glucose metabolism similar to those with prediabetes, finds an alarming study

The findings, published in JAMA Network Open, showed that men were more likely to develop diabetes than women

Policies assist those already suffering from the disease and most cost only around 20% more

Children and adolescents infected with COVID-19 show a substantially higher risk of developing type 1 diabetes (T1D), according to a study of over 1 million patients aged 18 and younger. The findings, published recently in the journal JAMA Network Open, showed a 72 per cent increase in new diagnoses of T1D in younger COVID-19 patients in the six months following their diagnosis. However, the research emphasised that it is unclear whether COVID-19 triggers new onset of T1D. "Type 1 diabetes is considered an autoimmune disease," said Pamela Davis, a professor at the Case Western Reserve School of Medicine, US, and corresponding author of the study. "It occurs mostly because the body's immune defenses attack the cells that produce insulin, thereby stopping insulin production and causing the disease. COVID has been suggested to increase autoimmune responses, and our present finding reinforces that suggestion," Davis said. The team analysed the de-identified electronic health records o

By 2040, Type 1 diabetes cases to increase by 116% in India, says Lancet study

An estimated 8.4 million people were living with Type 1 Diabetes across the globe in 2021, and India was among the top ten countries with highest prevalence of the disease, according to a modelling study published in The Lancet Diabetes & Endocrinology journal. This number is predicted to increase to 13.5-17.4 million people living with Type 1 Diabetes (T1D) by 2040, the resaerchers said. "Given that prevalence of people with T1D is projected to increase in all countries to up to 17.5 million cases in 2040, our results provide a warning for substantial negative implications for societies and healthcare systems," said Professor Graham Ogle, one of the authors of the study, from the University of Sydney, Australia. "There is an opportunity to save millions of lives in the coming decades by raising the standard of care for T1D and increasing awareness of the signs and symptoms of T1D to enable a 100 per cent rate of diagnosis in all countries," Ogle said. Researchers modelled data on

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations